A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.